Elysium Health � EH301

Elysium, founded by Leonard Guarente, is on a mission is to translate critical scientific advancements in aging research into accessible health products and technologies. The current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. At present Elysium markets four products: Basis, Matter, Format, Signal, and Index. Although these products are categorized as supplements rather than pharmaceuticals, Elysium is setting up clinical trials to establish thieir safety and effectiveness. As of May 2023 Elysium has 18 clinical trials listed on clinicaltrials.gov.. This foundation allows Elysium to establish an approach to scientific discovery and customer support that enables the pursuit of lifelong health and wellness. EH301 contains the same ingredients as Basis, but it is not clear if the dosage or proportion of each is the same. The objective of this trial is to evaluate the efficacy and tolerability of EH301 in patients with amyotrophic lateral sclerosis. Patients with ALS are randomized to receive either EH301 or placebo daily and undergo active evaluation for 6 months. This trial concluded that EH301 was safe and associated with improvements in several clinical measurements of ALS. Unfortunately, the trial had many significant flaws which limits confidence in its conclusions (https://www.alzforum.org/news/research-news/small-trial-eh301-appears-halt-progression-als). ClinicalTrials.gov Identifier: NCT03489200